Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Recurrence 1Primary Myelofibrosis 1Polycythemia 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Juvenile 1Disease 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 47Azacitidine 44fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 13Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × imetelstat × 1 year × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡